2010 full-year results 3 March 2011 - UCB

More documents

Recommendations

Info

Cimzia ® main message is unique and motivating Rheums who recall the 12 week message (unaided) rate the CIMZIA ® message significantly higher on unique and different and highest on motivation to prescribe Cimzia ® : Onset of Action** within 12 weeks (sub-subnet) Humira Actemra Simponi Cimzia ® (other messages) Enbrel Remicade Orencia Motivation to Prescribe Product (n=47) (n=49) (n=50) (n=50) (n=111) (n=50) (n=50) (n=49) 4.58 4.56 4.54 4.42 4.41 4.88 4.86 Cimzia ® : Onset of Action** within 12 weeks (sub-subnet) Actemra Simponi Cimzia ® : (Other messages) Humira Orencia Enbrel Remicade **Onset of Action is made up of codes: three month/twelve week free trial, ability to make an informed treatment decision in 12 weeks and rapid onset of action within 12 weeks. 5.32 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Mean Rating Uniqueness and Difference of Product (n=47) (n=50) (n=50) (n=111) (n=49) (n=49) (n=50) (n=50) 3.94 4.70 4.68 4.55 4.39 4.38 5.22 5.51 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Mean Rating 10
Cimzia ® in rheumatoid arthritis – U.S. Gaining use even in an entrenched marketplace RA Indexed Monthly Rx 240 220 200 180 160 140 120 100 80 Jan‐10 Feb‐10 Cimzia ® RA indexed vs Total Market: Mar‐10 Apr‐10 May‐10 Jun‐10 Jul‐10 Aug‐10 Sep‐10 Oct‐10 Nov‐10 Cimzia® Nrx Total Market Nrx Cimzia® Trx Total Market Trx Dec‐10 NRx = New prescriptions / TRx = Total prescriptions Source: IMS National Prescription Audit (NPA) 11
Page 1 and 2: 2010 full-year results 3 March 2011
Page 3 and 4: UCB: to be patient-centric global b
Page 5 and 6: 203 000 patients have now been trea
Page 7 and 8: U.S. Business Greg Duncan, Presiden
Page 9: Cimzia ® provides a fast response
Page 13 and 14: Vimpat ® U.S. When monotherapy is
Page 15 and 16: UCB’s status as the company with
Page 17 and 18: Physicians report Vimpat ® is the
Page 19 and 20: Cimzia ® Fast response for predict
Page 21 and 22: Cimzia ® roll-out in Europe and Re
Page 23 and 24: Vimpat ® in epilepsy Roll-out in E
Page 25 and 26: Neupro ® roll-out in Europe and Re
Page 27 and 28: Neupro ® - rotigotine transdermal
Page 29 and 30: 2010 Financial Performance Detlef T
Page 31 and 32: Net sales of major and new products
Page 33 and 34: Recurring EBITDA Consistent solid u
Page 35 and 36: 2010 cash flows FY 2009 cash € 46
Page 37 and 38: 2011 financial outlook Revenue is e
Page 39 and 40: Advancing the pipeline Iris Loew-Fr
Page 41 and 42: Development pipeline with significa
Page 43 and 44: Brivaracetam in epilepsy New Phase
Page 45 and 46: Additional external pipeline option
Page 47 and 48: UCB NewMedicines strategy and busin
Page 49 and 50: Attrition rates of failed Phase 3 c
Page 51 and 52: UCB2892 (H3 antagonist) January 201
Page 53 and 54: Significant Pipeline Q2 January pip
Page 55 and 56: UCB's Sustainable Growth Roch Doliv
Page 57 and 58: UCB's sustainable future growth Cim
Page 59 and 60: Appendix 59 59
Page 61 and 62:
Geographic and therapeutic breakdow
Page 63 and 64:
2010 balance sheet € million Cash
Page 65 and 66:
Shareholder structure 1 Strong and
Page 67 and 68:
Cimzia ® in further arthritis indi
Page 69 and 70:
CDP7851 in bone loss disorders Nove
Page 71 and 72:
Vimpat ® in epilepsy Increasing pa
Page 73:
Your UCB Investor Relations team An
show all

2010 full-year results 3 March 2011 - UCB

Create successful ePaper yourself

Delete template?

Save as template?